Amylyx Pharmaceuticals, Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs. The company’s current pipeline centers on endocrine and neurodegenerative disorders, with avexitide as its lead investigational program. Avexitide is being studied as a first-in-class GLP-1 receptor antagonist for conditions linked to excessive insulin activity, including post-bariatric hypoglycemia and congenital hyperinsulinism. Amylyx also advances additional investigational therapies across other rare and serious diseases, reflecting a research portfolio built around well-defined biological targets and measurable clinical outcomes. Headquartered in Cambridge, Massachusetts, Amylyx Pharmaceuticals plays a role in the biotechnology market as a developer of targeted treatments for patients facing limited therapeutic options.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Joshua B. Cohen
- Employees
- 136
- Headquarters
- Cambridge, MA, United States
- Website
- amylyx.com